Who are Glimepiride/metformin fixed combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glimepiride-metformin-fixed-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Glimepiride/metformin fixed combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glimepiride/metformin fixed combination (Glimepiride/metformin fixed combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea/biguanide combination. Area: Diabetes.

marketed Sulfonylurea/biguanide combination ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Glimepiride/metformin fixed combination (Glimepiride/metformin fixed combination) — Handok Inc.. This combination reduces blood glucose by stimulating insulin secretion from pancreatic beta cells (glimepiride) and decreasing hepatic glucose production while improving insulin sensitivity (metformin).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Glimepiride/metformin fixed combination TARGET	Glimepiride/metformin fixed combination	Handok Inc.	marketed	Sulfonylurea/biguanide combination	ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea/biguanide combination class)

Handok Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glimepiride/metformin fixed combination — Competitive Intelligence Brief. https://druglandscape.com/ci/glimepiride-metformin-fixed-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab